RIPK2 is a serine/threonine kinase essential for innate and adaptive immune responses 1. It functions as a key effector of NOD1 and NOD2 signaling pathways by recruiting to activated pattern recognition receptors upon bacterial peptidoglycan detection, where it undergoes autophosphorylation and K63-linked polyubiquitination by XIAP and BIRC proteins, as well as linear polyubiquitination by the LUBAC complex 1. These ubiquitin modifications enable RIPK2 to scaffold downstream signaling complexes that activate NF-κB and MAPK pathways, ultimately promoting inflammatory cytokine production 1. Notably, RIPK2's kinase activity is dispensable for NOD-mediated signaling, functioning primarily as a scaffolding protein 1. RIPK2 also participates in T-cell receptor signaling and NOD1-dependent hematopoietic stem cell specification through NF-κB activation 2. Dysregulation of RIPK2 has clinical implications: genetic variants in RIPK2 are associated with Crohn's disease susceptibility, and RIPK2 plays roles in neuroinflammatory diseases including Alzheimer's disease and multiple sclerosis 13. Recent evidence demonstrates RIPK2 is a therapeutic target in pancreatic cancer, where tumor-intrinsic RIPK2 drives immune evasion by impairing MHC class I presentation, and RIPK2 inhibition combined with anti-PD-1 immunotherapy enhances anti-tumor immunity 4.